Abstract:IL‐33 isoforms generated through allergen‐driven proteolysis, signal through NF‐κB at varying intensities. The magnitude of IL‐33 signalling is determined by asthma‐associated structural variation in IL33 receptor. Variation in the IL‐33 receptor extracellular domain alters accessibility of the IL‐33 ligand binding site. Introduction The interleukin‐33/interleukin‐1 receptor‐like‐1 (IL‐33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway. Method In a project funded by GSK plc, which has developed an IL‐33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa‐beta (NF‐κB) promoter, were transiently transfected with IL1RL1, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic‐generated IL‐33 isoforms (0.001–50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin‐8 (IL‐8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL‐33112–270 (50 ng/mL) and induced IL‐8 mRNA expression measured. Results HEK293 cells carrying both asthma extracellular and TIR domain IL1RL1 risk haplotypes presented maximal IL33‐driven signalling, with minimal signalling after IL‐33 activation in other protective haplotypes. All IL‐33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL3395–270 and IL33106–270 had the greatest effect and the IL33113–270, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes. Conclusions Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL3395–270 and IL33106–270 may be more amenable to IL33/IL1RL1 targeting.

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

IL-33 Promotes Airway Remodeling and is a Marker of Asthma Disease Severity

Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases

Interleukin-31 Expression and Relation to Disease Severity in Human Asthma.

Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype

Phenotypic and functional translation of IL33 genetics in asthma

IL-33 amplifies airways inflammation in a murine surrogate of asthma possibly through acting on dendritic cells

IL-33 Promotes Airway Remodeling in Asthma Through ST2/ERK1/2/MSK1 Signal Pathway

[The Levels and Clinical Implications of Induced Sputum Interleukin-17 in Chronic Obstructive Pulmonary Disease and Asthma].

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

The levels of interleukin 17 in induced sputum in patients with severe asthma and its relationship to airway inflammation and airflow limitation

The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease.

Epithelial Interleukin‐1 Receptor‐Like‐1 Activation Is Contingent on Interleukin‐33 Isoforms and Asthma‐Related Receptor Variation

Effect of Interleukin-33 on Th1/Th2 Cytokine Ratio in Peripheral Lymphocytes in Asthmatic Mice.

Elevated sputum IL-36 levels are associated with neutrophil-related inflammation in COPD patients

IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status

IL-33's role in NET formation and neutrophil-mediated inflammation in smoke-exposed asthma through autophagy

Expression and Implications of Human Interleukin-32 in Acute Exacerbation with Chronic Obstructive Pulmonary Disease

The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases

IL-33/ST2 immune responses to respiratory bacteria in pediatric asthma

Expression of Serum ADAM33 in Patients with Different Severity of Asthma and the Relation to Airway Chronic Inflammation